Medrx Co CROIC

Mitä Medrx Co tekee? Medrx Co Ltd is a pharmaceutical company based in Higashikagawa-shi, Japan, operating within the Health Care sector. The company has 22 employees and went public on February 13, 2013, with its ticker listed as 4586.T on the Tokyo Stock Exchange. Medrx focuses on pharmaceutical drug development utilizing transdermal absorption technology. The company's website is www.medrx.co.jp. Medrx develops new medicines using percutaneous absorption formulation technology, specifically employing ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). These technologies leverage ionic liquid characteristics and nano colloidization to enhance drug efficacy, minimize side effects, and provide alternative administration methods for patients who cannot take medications orally. The company aims to create medicines with innovative value by addressing challenges such as patient compliance and delivery methods for difficult-to-administer drugs. Medrx is headquartered in Higashikagawa-shi, Kagawa Prefecture, and maintains a small operational scale with a dedicated team of 22 full-time employees. The company's business model centers on developing pharmaceuticals that improve patient outcomes through advanced transdermal delivery systems, targeting specific medical needs where traditional oral administration is impractical or ineffective. Medrx Co on yksi Eurpooliin suosituimmista yhtiöistä.